Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
Antoinette R TanJoyce O'ShaughnessySubing CaoSarah AhnJohn S YiPublished in: Breast cancer research and treatment (2023)
The results suggest that administering trilaciclib prior to GCb may modulate the composition and response of immune cell subsets to TNBC.